Diagnosis and Management of Immune Checkpoint Inhibitor–related Toxicities in Ovarian Cancer: A Series of Case Vignettes
Use of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death protein 1 have led to improved survival outcomes for advanced solid-tumor malignancies. This report helps the reader gain a better understanding of adverse events in patients with ovar...
Gespeichert in:
| Veröffentlicht in: | Clinical therapeutics 2018-03, Vol.40 (3), p.389-394 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 394 |
|---|---|
| container_issue | 3 |
| container_start_page | 389 |
| container_title | Clinical therapeutics |
| container_volume | 40 |
| creator | Johnson, Cynae Jazaeri, Amir Anthony |
| description | Use of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death protein 1 have led to improved survival outcomes for advanced solid-tumor malignancies. This report helps the reader gain a better understanding of adverse events in patients with ovarian cancer on checkpoint inhibitor therapy. We describe 3 hypothetical case vignettes of patients with gynecologic cancer on checkpoint inhibitor immunotherapy and discuss common immune-related adverse events. The typical presentation and onset of immune-related events are different from those associated with conventional chemotherapy. This report highlights the importance of early recognition and management of these events. |
| doi_str_mv | 10.1016/j.clinthera.2018.02.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2012918604</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291818300614</els_id><sourcerecordid>2012918604</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-b7f29f81e803e137a79b6783047989478aaea4717196ba2ace440029997f0ea83</originalsourceid><addsrcrecordid>eNqFkc2O0zAUhS0EYsrAK4AlNmwS7MStbXZV-Ks0aBYMiJ1149y0Lo3dsZMRsOIdeEOeBEcdZsGG1V3c75x7dQ4hzzgrOeOrl_vSHpwfdxihrBhXJatKxvk9suBK6oJz8eU-WTAudFFprs7Io5T2jLFaL6uH5KzSS64lXy7Ij9cOtj4klyj4jn4AD1sc0I809HQzDJNH2uzQfj2GfI9u_M61bgzx989fEQ8wYkevwjdn3egwUefp5Q1EB5424C3GV3RNP2Kcd9mvgYT0s9t6HEdMj8mDHg4Jn9zOc_Lp7Zur5n1xcflu06wvCiuEGotW9pXuFUfFauS1BKnblVQ1E1IrLaQCQBCSS65XLVRgUQjGKq217BmCqs_Ji5PvMYbrCdNoBpcsHg7gMUzJ5PzmjFZMZPT5P-g-TNHn72ZK1JJlNlPyRNkYUorYm2N0A8TvhjMz12P25q6eWagMq0yuJyuf3vpP7YDdne5vHxlYnwDMgdw4jCZZhznJzkW0o-mC---RP7JPpYg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2014370012</pqid></control><display><type>article</type><title>Diagnosis and Management of Immune Checkpoint Inhibitor–related Toxicities in Ovarian Cancer: A Series of Case Vignettes</title><source>Elsevier ScienceDirect Journals</source><creator>Johnson, Cynae ; Jazaeri, Amir Anthony</creator><creatorcontrib>Johnson, Cynae ; Jazaeri, Amir Anthony</creatorcontrib><description>Use of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death protein 1 have led to improved survival outcomes for advanced solid-tumor malignancies. This report helps the reader gain a better understanding of adverse events in patients with ovarian cancer on checkpoint inhibitor therapy. We describe 3 hypothetical case vignettes of patients with gynecologic cancer on checkpoint inhibitor immunotherapy and discuss common immune-related adverse events. The typical presentation and onset of immune-related events are different from those associated with conventional chemotherapy. This report highlights the importance of early recognition and management of these events.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2018.02.011</identifier><identifier>PMID: 29519715</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>anti-CTLA-4 ; anti-PD1 ; Apoptosis ; Cancer ; Cancer therapies ; Cell death ; Chemotherapy ; Clinical trials ; Cytotoxicity ; Drug dosages ; Family medical history ; FDA approval ; hypophysitis ; Immune checkpoint inhibitors ; Immune system ; Immunotherapy ; Inhibitors ; Lymphocytes T ; Medical diagnosis ; Medical research ; Medicine ; Oncology ; Ovarian cancer ; Patients ; pneumonitis ; thyroiditis ; Tomography ; Toxicity ; Tumors</subject><ispartof>Clinical therapeutics, 2018-03, Vol.40 (3), p.389-394</ispartof><rights>2018 Elsevier HS Journals, Inc.</rights><rights>Copyright © 2018 Elsevier HS Journals, Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Mar 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-b7f29f81e803e137a79b6783047989478aaea4717196ba2ace440029997f0ea83</citedby><cites>FETCH-LOGICAL-c448t-b7f29f81e803e137a79b6783047989478aaea4717196ba2ace440029997f0ea83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0149291818300614$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29519715$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Johnson, Cynae</creatorcontrib><creatorcontrib>Jazaeri, Amir Anthony</creatorcontrib><title>Diagnosis and Management of Immune Checkpoint Inhibitor–related Toxicities in Ovarian Cancer: A Series of Case Vignettes</title><title>Clinical therapeutics</title><addtitle>Clin Ther</addtitle><description>Use of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death protein 1 have led to improved survival outcomes for advanced solid-tumor malignancies. This report helps the reader gain a better understanding of adverse events in patients with ovarian cancer on checkpoint inhibitor therapy. We describe 3 hypothetical case vignettes of patients with gynecologic cancer on checkpoint inhibitor immunotherapy and discuss common immune-related adverse events. The typical presentation and onset of immune-related events are different from those associated with conventional chemotherapy. This report highlights the importance of early recognition and management of these events.</description><subject>anti-CTLA-4</subject><subject>anti-PD1</subject><subject>Apoptosis</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cell death</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Cytotoxicity</subject><subject>Drug dosages</subject><subject>Family medical history</subject><subject>FDA approval</subject><subject>hypophysitis</subject><subject>Immune checkpoint inhibitors</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Inhibitors</subject><subject>Lymphocytes T</subject><subject>Medical diagnosis</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Patients</subject><subject>pneumonitis</subject><subject>thyroiditis</subject><subject>Tomography</subject><subject>Toxicity</subject><subject>Tumors</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc2O0zAUhS0EYsrAK4AlNmwS7MStbXZV-Ks0aBYMiJ1149y0Lo3dsZMRsOIdeEOeBEcdZsGG1V3c75x7dQ4hzzgrOeOrl_vSHpwfdxihrBhXJatKxvk9suBK6oJz8eU-WTAudFFprs7Io5T2jLFaL6uH5KzSS64lXy7Ij9cOtj4klyj4jn4AD1sc0I809HQzDJNH2uzQfj2GfI9u_M61bgzx989fEQ8wYkevwjdn3egwUefp5Q1EB5424C3GV3RNP2Kcd9mvgYT0s9t6HEdMj8mDHg4Jn9zOc_Lp7Zur5n1xcflu06wvCiuEGotW9pXuFUfFauS1BKnblVQ1E1IrLaQCQBCSS65XLVRgUQjGKq217BmCqs_Ji5PvMYbrCdNoBpcsHg7gMUzJ5PzmjFZMZPT5P-g-TNHn72ZK1JJlNlPyRNkYUorYm2N0A8TvhjMz12P25q6eWagMq0yuJyuf3vpP7YDdne5vHxlYnwDMgdw4jCZZhznJzkW0o-mC---RP7JPpYg</recordid><startdate>201803</startdate><enddate>201803</enddate><creator>Johnson, Cynae</creator><creator>Jazaeri, Amir Anthony</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201803</creationdate><title>Diagnosis and Management of Immune Checkpoint Inhibitor–related Toxicities in Ovarian Cancer: A Series of Case Vignettes</title><author>Johnson, Cynae ; Jazaeri, Amir Anthony</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-b7f29f81e803e137a79b6783047989478aaea4717196ba2ace440029997f0ea83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>anti-CTLA-4</topic><topic>anti-PD1</topic><topic>Apoptosis</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cell death</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Cytotoxicity</topic><topic>Drug dosages</topic><topic>Family medical history</topic><topic>FDA approval</topic><topic>hypophysitis</topic><topic>Immune checkpoint inhibitors</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Inhibitors</topic><topic>Lymphocytes T</topic><topic>Medical diagnosis</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Patients</topic><topic>pneumonitis</topic><topic>thyroiditis</topic><topic>Tomography</topic><topic>Toxicity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Johnson, Cynae</creatorcontrib><creatorcontrib>Jazaeri, Amir Anthony</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Johnson, Cynae</au><au>Jazaeri, Amir Anthony</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diagnosis and Management of Immune Checkpoint Inhibitor–related Toxicities in Ovarian Cancer: A Series of Case Vignettes</atitle><jtitle>Clinical therapeutics</jtitle><addtitle>Clin Ther</addtitle><date>2018-03</date><risdate>2018</risdate><volume>40</volume><issue>3</issue><spage>389</spage><epage>394</epage><pages>389-394</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>Use of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death protein 1 have led to improved survival outcomes for advanced solid-tumor malignancies. This report helps the reader gain a better understanding of adverse events in patients with ovarian cancer on checkpoint inhibitor therapy. We describe 3 hypothetical case vignettes of patients with gynecologic cancer on checkpoint inhibitor immunotherapy and discuss common immune-related adverse events. The typical presentation and onset of immune-related events are different from those associated with conventional chemotherapy. This report highlights the importance of early recognition and management of these events.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29519715</pmid><doi>10.1016/j.clinthera.2018.02.011</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2918 |
| ispartof | Clinical therapeutics, 2018-03, Vol.40 (3), p.389-394 |
| issn | 0149-2918 1879-114X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2012918604 |
| source | Elsevier ScienceDirect Journals |
| subjects | anti-CTLA-4 anti-PD1 Apoptosis Cancer Cancer therapies Cell death Chemotherapy Clinical trials Cytotoxicity Drug dosages Family medical history FDA approval hypophysitis Immune checkpoint inhibitors Immune system Immunotherapy Inhibitors Lymphocytes T Medical diagnosis Medical research Medicine Oncology Ovarian cancer Patients pneumonitis thyroiditis Tomography Toxicity Tumors |
| title | Diagnosis and Management of Immune Checkpoint Inhibitor–related Toxicities in Ovarian Cancer: A Series of Case Vignettes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T18%3A29%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diagnosis%20and%20Management%20of%20Immune%20Checkpoint%20Inhibitor%E2%80%93related%20Toxicities%20in%20Ovarian%20Cancer:%20A%20Series%20of%20Case%20Vignettes&rft.jtitle=Clinical%20therapeutics&rft.au=Johnson,%20Cynae&rft.date=2018-03&rft.volume=40&rft.issue=3&rft.spage=389&rft.epage=394&rft.pages=389-394&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2018.02.011&rft_dat=%3Cproquest_cross%3E2012918604%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2014370012&rft_id=info:pmid/29519715&rft_els_id=S0149291818300614&rfr_iscdi=true |